Caricamento...

Phase II Study of Daily Sunitinib in FDG-PET Positive, Iodine Refractory, Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid with Functional Imaging Correlation

PURPOSE: We conducted a phase II study to assess the efficacy of continuous dosing of sunitinib in patients with FDG-PET avid, iodine refractory, well-differentiated thyroid carcinoma (WDTC) and medullary thyroid cancer (MTC), and to assess for early response per FDG-PET. EXPERIMENTAL DESIGN: Patien...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Carr, Laurie L., Mankoff, David A., Goulart, Bernardo H., Eaton, Keith D., Capell, Peter T., Kell, Elizabeth M., Bauman, Julie E., Martins, Renato G.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3063514/
https://ncbi.nlm.nih.gov/pubmed/20847059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-0994
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !